GAMA
Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting

The earliest phase of HIV infection is clinically important in determining the natural history of disease. It is also the moment in which much of the immune damage occurs and constitutes the most infectious stage of the infection. Development of a test which could distinguish between individuals with early or longstanding HIV infection could potentially be used for clinical management, but would also allow the estimation of an HIV incidence rate.
The primary aim of GAMA is to gain a better understanding of dynamics of biomarkers of gastrointestinal inflammation during the first year of HIV infection as compared to chronic infection. The tremendous damage inflicted on the gut-associated lymphoid tissue during early HIV infection may provide the opportunity to identify biomarkers which present altered expression during the early phases of HIV infection. GAMA will assess the utility of these markers for identifying recent HIV infection as well as for potential associations with progression to AIDS. Understanding the dynamics of these biomarkers and associating them with standard serological responses during early HIV infection may reveal specific changes in expression patterns of biomarkers which are able to distinguish early from longstanding HIV infection.
Development of an assay for measuring HIV incidence would facilitate the evaluation of ongoing prevention programs as well as the design and implementation of trials to evaluate new prevention interventions.
Project Funders
Main Funders: Bill & Mellinda Gates Foundation
Co-funding: Ministry of Economy and Competitiveness. Government of Spain
Nuestro equipo
Principal Investigator (PI)
-
Denise Suzanne Naniche
Otros proyectos
Ver proyectos pasadosCARE
Linkage and retention in care following home-based HIV testing serosurveys in Manhiça District, Southern Mozambique
Xpatial-TB
Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique
WHIP3TB
Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals
METRO
Measuring community prevalence among HIV exposed children in rural Southern Mozambique
MAMAH
Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women
VINCI
Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique
INTE-AFRICA
Integrating and decentralizing diabetes and hypertension services in Africa
PreFIT
Predicting the Future: Incipient Tuberculosis
2G Color Plates
2nd Generation Color Agar Plates to Diagnose MDR-Tuberculosis: a Prospective Pilot Study